News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
ULURU Inc. Release: Zindaclin Licensing Collaborations Extended To Include Italy And Spain
November 22, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DALLAS--(BUSINESS WIRE)--Nov. 22, 2005--ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTCBB:OXFV) today announced the expansion of the European licensing of Zindaclin to include Italy and Spain.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Editorial
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
October 8, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
October 8, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart
October 8, 2026
·
2 min read
·
Gabrielle Masson
Funding
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
October 8, 2026
·
1 min read
·
Tristan Manalac